Coherus Biosciences Inc (CHRS) Receives $30.20 Average Target Price from Brokerages
Coherus Biosciences Inc (NASDAQ:CHRS) has been assigned an average rating of “Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $28.33.
Several brokerages recently commented on CHRS. Zacks Investment Research upgraded Coherus Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Wednesday. Maxim Group set a $25.00 target price on Coherus Biosciences and gave the company a “buy” rating in a report on Friday, May 10th. ValuEngine raised Coherus Biosciences from a “hold” rating to a “buy” rating in a report on Friday, May 10th. HC Wainwright started coverage on Coherus Biosciences in a report on Tuesday, May 7th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, BidaskClub raised Coherus Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday, April 30th.
Shares of NASDAQ:CHRS traded up $0.69 during mid-day trading on Friday, hitting $17.56. 560,268 shares of the company traded hands, compared to its average volume of 815,106. The company has a market cap of $1.18 billion, a P/E ratio of -5.45 and a beta of 3.64. The company has a debt-to-equity ratio of 8.29, a quick ratio of 2.49 and a current ratio of 3.84. Coherus Biosciences has a 52-week low of $8.32 and a 52-week high of $20.66.
In other Coherus Biosciences news, CFO Jean-Frederic Viret sold 3,000 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $14.92, for a total value of $44,760.00. Following the sale, the chief financial officer now owns 13,185 shares of the company’s stock, valued at $196,720.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.20% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its stake in shares of Coherus Biosciences by 12.3% during the fourth quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 998 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Coherus Biosciences in the 1st quarter worth about $108,000. Roman Butler Fullerton & Co. purchased a new position in shares of Coherus Biosciences in the 4th quarter worth about $122,000. Principal Financial Group Inc. purchased a new position in shares of Coherus Biosciences in the 1st quarter worth about $145,000. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Coherus Biosciences by 107,870.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,797 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 10,787 shares during the period. 96.20% of the stock is currently owned by institutional investors.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Featured Article: The primary rules of Elliott Wave theory
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.